open access

Vol 11, No 2 (2007)
REVIEV
Published online: 2007-05-18
Get Citation

Effects of antihypertensive drugs on uric acid level

Katarzyna Kostka-Jeziorny, Andrzej Tykarski
Nadciśnienie tętnicze 2007;11(2):151-163.

open access

Vol 11, No 2 (2007)
REVIEV
Published online: 2007-05-18

Abstract

We summarized recent published literature regarding the influence of antihypertensive agents on uric acid level. Hyperuricemia is associated with risk for cardiovascular disease and death. However, the role of uric acid independent of established risk factor is uncertain. Recently researchers have drawn attention to a putative role of uric acid in pathogenesis of hypertension and renal disease. Uric acid levels are largely ignored in medical practice. An increase in serum uric acid levels has been observed during treatment with thiazide and loop diuretics and β-blockers, but treatment with β-blockers seems in most cases to be of no clinical importance. Calcium channel blockers have uricosuric effects, but decrease of uric acid level is not significant. Angiotensin converting enzymes inhibitors (ACE-I) and some of angiotensin II type 1 receptor antagonists (ARB) cause significant reduction of uric acid concentration. A feature of losartan that differentiates it from other ARB is its lowering in the largest degree of serum uric acid. Beyond typical mechanism for RAA blocking agents as hemodynamic renal blood flow increase and uric acid secretion, the losartan molecule is due to interfere with urate reabsorption in the renal proximal tubule.
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, which was designed to compare the effects of losartan and atenolol, has shown more clinical benefit during treatment with losartan. It is recommended that baseline uric acid level and antihypertensive treatment influence on uric acid concentration shoud be studied before starting and continuation of chosen antihypertensive therapy.

Abstract

We summarized recent published literature regarding the influence of antihypertensive agents on uric acid level. Hyperuricemia is associated with risk for cardiovascular disease and death. However, the role of uric acid independent of established risk factor is uncertain. Recently researchers have drawn attention to a putative role of uric acid in pathogenesis of hypertension and renal disease. Uric acid levels are largely ignored in medical practice. An increase in serum uric acid levels has been observed during treatment with thiazide and loop diuretics and β-blockers, but treatment with β-blockers seems in most cases to be of no clinical importance. Calcium channel blockers have uricosuric effects, but decrease of uric acid level is not significant. Angiotensin converting enzymes inhibitors (ACE-I) and some of angiotensin II type 1 receptor antagonists (ARB) cause significant reduction of uric acid concentration. A feature of losartan that differentiates it from other ARB is its lowering in the largest degree of serum uric acid. Beyond typical mechanism for RAA blocking agents as hemodynamic renal blood flow increase and uric acid secretion, the losartan molecule is due to interfere with urate reabsorption in the renal proximal tubule.
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, which was designed to compare the effects of losartan and atenolol, has shown more clinical benefit during treatment with losartan. It is recommended that baseline uric acid level and antihypertensive treatment influence on uric acid concentration shoud be studied before starting and continuation of chosen antihypertensive therapy.
Get Citation

Keywords

uric acid; hyperuricemia; hypertension; antihypertensive treatment

About this article
Title

Effects of antihypertensive drugs on uric acid level

Journal

Arterial Hypertension

Issue

Vol 11, No 2 (2007)

Pages

151-163

Published online

2007-05-18

Bibliographic record

Nadciśnienie tętnicze 2007;11(2):151-163.

Keywords

uric acid
hyperuricemia
hypertension
antihypertensive treatment

Authors

Katarzyna Kostka-Jeziorny
Andrzej Tykarski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl